Risk of cancer-specific mortality following recurrence after radical nephroureterectomy

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4337-4344

  Rink, Michael ^a,b   Sjoberg, Daniel ^c   Comploj, Evi ^d   Margulis, Vitaly ^e   Xylinas, Evanguelos ^a,f   Lee, Richard K ^a   Hansen, Jens ^b,g   Cha, Eugene K ^a   Raman, Jay D ^h   Remzi, Mesut ⁱ   Bensalah, Karim ^j   Novara, Giacomo ^k   Matin, Surena F ^l   Chun, Felix K ^b   Kikuchi, Eiji ^m   Kassouf, Wassim ⁿ   Martinez Salamanca, Juan I ^o   Lotan, Yair ^e   Seitz, Christian ^p   Pycha, Armin ^d   Zigeuner, Richard ^q   Karakiewicz, Pierre I ^g   Scherr, Douglas S ^a   Vickers, Andrew J ^c   Shariat, Shahrokh F ^a   more..

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CENTRAL HOSPITAL OF BOLZANO   (Italy)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Paris Descartes University ^*  (France)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

ⁱ Hospital Weinviertel Korneuburg   (Austria)

^j UNIVERSITÉ DE RENNES 1   (France)

^k UNIVERSITY OF PADOVA   (Italy)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^o HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^p MEDICAL UNIVERSITY OF VIENNA   (Austria)

^q MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DECISION MAKING; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROURETERECTOMY; PATIENT COUNSELING; POSTOPERATIVE COMPLICATION; PROPORTIONAL HAZARDS MODEL; RADICAL NEPHROURETERECTOMY; RADICAL RESECTION; RECURRENT DISEASE; STRATIFIED SAMPLE; TRANSITIONAL CELL CARCINOMA; TUMOR LOCALIZATION;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; URETERAL NEOPLASMS;

EID: 84876470645     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2499-8     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224-33.
3. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol. 2011;59:584-94.
4. Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract uro-thelial carcinoma. Eur Urol. 2012;61:818-25.
5. Kikuchi E, Margulis V, Karakiewicz P, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27:612-8.
6. Chromecki TF, Bensalah K, Remzi M, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8:440-7.
7. Novara G, Matsumoto K, Kassouf W, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol. 2010;57:1064-71.
8. Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103: 307-11.
9. Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010;57:575-81.
10. Chromecki TF, Cha EK, Fajkovic H, et al. The impact of tumor multifocality on outcomes in patients treated with radical neph-roureterectomy. Eur Urol. 2012;61:245-53.
11. Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) staging manual. 7th ed. New York: Springer; 2010.
12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
13. Rink M, Ehdaie B, Cha EK, et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 2012. doi:10.1016/j.eururo.2012. 02.018.
14. Rink M, Fajkovic H, Cha EK, et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol. 2012;61:854-5.
15. Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladDer cancer following radical cystec-tomy. BJU Int. 2012;109(6):846-54.
16. Langner C, Hutterer G, Chromecki T, et al. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. Mod Pathol. 2006;19:272-9. (Pubitemid 43117612)
17. Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110:1715-22. (Pubitemid 47557295)
18. Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2010;75:118-24.
19. Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57:1072-9.
20. Roscigno M, Brausi M, Heidenreich A, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 2011;60:776-83.
21. Yafi FA, Novara G, Shariat SF, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladDer cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int. 2012;110(2b):E7-13.
22. Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol. 2007;52:1414-8.
23. Miyake H, Hara I, Gohji K, et al. The significance of lymphad-enectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol. 1998;82:494-8. (Pubitemid 28477288)
24. Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol. 2008;53:794-802.
25. O'Donnell PH, Stadler WM. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol. 2009;419028.
26. Youssef RF, Shariat SF, Lotan Y, et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2011;108:1286-91.
27. Kondo T, Tanabe K. The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract. Int J Clin Oncol. 2011;16:170-8.
28. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62(1):100-14.
29. Ouzzane A, Colin P, Xylinas E, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in uro-thelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol. 2011;60:1258-65.
30. Zigeuner RE, Hutterer G, Chromecki T, et al. BladDer tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98:1181-6. (Pubitemid 44721221)
31. Waldert M, Karakiewicz P, Raman J, et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int. 2010;105: 812-7.
32. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-81. (Pubitemid 29470648)
33. Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009;182:900-6.
34. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladDer cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315-25.
35. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladDer cancer. Urol Oncol. 2010;28:389-400.